The Tecan Group announced that it has successfully completed the acquisition of a supplier of key parts. On March 22, 2019, Tecan announced the acquisition of a long-term supplier to vertically integrate the manufacturing of critical precision-machined parts. With two manufacturing sites, o ... more
Achim von Leoprechting promoted to become CEO of Tecan after retirement of David Martyr
The Tecan Group announced the retirement of Tecan CEO Dr David Martyr after 6 1/2 years at the helm of the company. The Board of Directors has appointed Dr Achim von Leoprechting, Head of Tecan's Partnering Business division, as the new Chief Executive Officer. He will assume the CEO role on April 1, 2019. Achim von Leoprechting will continue in his role as Head of the Partnering Business Division in addition to the new position until a successor for this role has been appointed.
Dr Lukas Braunschweiler, Chairman of Tecan's Board of Directors commented: "After another very successful business year 2018, Tecan is in a strong position with tremendous opportunities for the future. With Achim von Leoprechting, we have found an ideal candidate for the CEO succession. It is the first time in the history of Tecan that the Board was able to pick an internal successor - a clear evidence of the strong leadership team that was formed in recent years. The internal appointment also maximizes continuity of the corporate strategy."
Tecan CEO Dr David Martyr said: "I am very pleased that the Board has appointed Achim von Leoprechting as the new CEO of Tecan. He has an ideal background to lead Tecan through his extensive experience in both the life science research and in-vitro diagnostic industries. Under Achim von Leoprechting's leadership, Tecan's Partnering Business has grown by an average rate of more than 9% per year and, with several newly signed development and supply agreements, it is well positioned for further growth. His deep understanding of the end markets and his application expertise will help the company to further benefit from major growth drivers and expand Tecan's position as a complete solution provider in select applications."
Dr Achim von Leoprechting said: "Tecan is a leading provider and well-respected brand in our industry and I am very excited taking on the CEO position of such an exceptional company. In a very dynamic environment that many refer to as the 'century of biology', I very much look ahead to continue the successful development of Tecan together with my colleagues in the leadership team and all the dedicated and talented colleagues around the World."
Achim von Leoprechting joined Tecan in October 2013 as a member of the Management Board and Head of the Partnering Business division. He has 20 years of experience in a wide range of management positions in the life science industry. From 2002-2013, he has worked in various areas and held diverse positions with increasing management responsibility at PerkinElmer Inc., most recently as a Vice President and General Manager in the Life Science division.
Achim von Leoprechting has a doctorate in biology from the University of Freiburg (Germany). He is 50 years old and a German national.
"David Martyr has put Tecan back on a strong growth track and significantly expanded profitability", concluded Lukas Braunschweiler. "During his tenure, Tecan's sales expanded by over 50% since 2012, with around two thirds of the increase derived from organic growth, mainly through product innovation and regional expansion. Of particular note is the share of recurring revenues, which has increased in recent years from about 30% to now around 42% of overall sales, including first time contributions from smart consumables and reagents from synergetic M&A transactions. The Board of Directors sincerely thanks David Martyr for these outstanding accomplishments and wishes him the very best for his retirement."
- personnel changes
The Tecan Group announced that Dr. Klaus Lun, Head of Corporate Development and a member of the Management Board of the Tecan Group since June 2013, has been appointed Head of the Life Sciences Business division. On December 14, 2016, Tecan announced that Dr. Stefan Traeger, Head of the Lif ... more
The Tecan Group announced the acquisition of US-based SPEware Corporation (SPEware) to further expand Tecan's dedicated solutions offering into a new market segment. SPEware is a leading provider for mass spectrometry sample preparation solutions, with a focus on the North American market. ... more
- 1A new, highly sensitive chemical sensor uses protein nanowires
- 2New COVID-19 test quickly and accurately detects viral RNA
- 3Researcher Develops One Minute Coronavirus Test
- 4The Higgs boson and superconductivity
- 5Start-up Raises 16.3 million Euros to Prepare Market Launch of its SARS-CoV-2 Rapid Testing System
- 6Diagnostic biosensor quickly detects SARS-CoV-2 from nasopharyngeal swabs
- 7A new biosensor for the COVID-19 virus
- 8A Glimpse into Real-Time Methanol Synthesis
- 9Single-cell RNA seq method developed to accurately quantify cell-specific drug effects in pancreatic islets
- 10Real-time observation of enzymatic processes on DNA
- FRITSCH Change of Generations
- Achim von Leoprechting promoted to become CEO of Tecan after retirement of D ...
- PerkinElmer appoints President & Chief Operating Officer
- Merck Announces Future Insight Prize for Groundbreaking Scientific Work
- New Chief Financial Officers Appointed at Carl Zeiss AG and Carl Zeiss Medit ...